Spruce Biosciences (SPRB) EPS (Basic) (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly EPS (Basic) of -$15.77 for Q1 2026, up 34.94% year-over-year from -$11.69 in Q1 2025, and down 8.67% quarter-over-quarter from -$14.51 in Q4 2025.
Spruce Biosciences (SPRB) EPS (Basic) (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported EPS (Basic) for 8 consecutive years, with -$15.77 the latest figure, recorded in Q1 2026.
- In Q1 2026, EPS (Basic) rose 34.94% year-over-year to -$15.77; the TTM figure through Mar 2026 stood at -$31.37 (up 66.91% YoY), while the FY2025 annual figure was -$50.4, up 47.77% from the prior year.
- EPS (Basic) declined to -$15.77 in Q1 2026 per SPRB's latest filing, from -$14.51 in the prior quarter.
- Across five years, EPS (Basic) topped out at -$3.5 in Q2 2025 and bottomed at -$42.68 in Q4 2024.
- Historically, EPS (Basic) has averaged -$24.84 across 5 years, with a median of -$24.24 in 2025.
- Annual changes were most pronounced in 2024 — EPS (Basic) tumbled 94.46% — and 2025, when it surged 79.1%.
- Spruce Biosciences' EPS (Basic) stood at -$32.2 in 2022, then surged by 31.84% to -$21.95 in 2023, then slumped by 94.46% to -$42.68 in 2024, then soared by 66.0% to -$14.51 in 2025, then declined by 8.67% to -$15.77 in 2026.
- Business Quant data shows SPRB's EPS (Basic) at -$15.77 in Q1 2026, -$14.51 in Q4 2025, and -$14.58 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.65 Bn | 131.79 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 86.08 Bn | 78.09 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn | 7.59 |
| 4 | Moderna | 63.25 Bn | 58.11 Bn | 52.00 Mn | -1.96 |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 2.12 |
| 6 | Alnylam Pharmaceuticals | 31.26 Bn | 27.95 Bn | 992.69 Mn | 1.23 |
| 7 | BioNTech SE | 28.96 Bn | 10.57 Bn | 668.28 Mn | -0.72 |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | -0.06 |
| 9 | Royalty Pharma | 27.19 Bn | 26.35 Bn | - | 0.18 |
| 10 | Spruce Biosciences | 127.00 Mn | 127.00 Mn | - | -6.93 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.41 |
| Mar 31, 2026 | -15.77 |
| Dec 31, 2025 | -14.51 |
| Sep 30, 2025 | -14.58 |
| Jun 30, 2025 | -3.50 |
| Mar 31, 2025 | -24.24 |
| Dec 31, 2024 | -42.68 |
| Sep 30, 2024 | -15.75 |
| Jun 30, 2024 | -16.73 |
| Mar 31, 2024 | -21.22 |
| Dec 31, 2023 | -21.95 |
| Sep 30, 2023 | -25.29 |
| Jun 30, 2023 | -25.84 |
| Mar 31, 2023 | -30.68 |
| Dec 31, 2022 | -32.20 |
| Sep 30, 2022 | -38.73 |
| Jun 30, 2022 | -39.74 |
| Mar 31, 2022 | -38.94 |
| Dec 31, 2021 | -30.90 |
| Sep 30, 2021 | -59.40 |